Metrics tell you whether the business is mechanically viable. They do not tell you whether the business is worth owning. Four qualitative factors carry as much weight as anything in the dashboard, and a clean dashboard cannot rescue a deal that fails on them.
Team: the founders are the asset. At seed and Series A the underwriting is overwhelmingly a bet on the founders. Look for clear role boundaries (who decides what), full-time commitment from the founding team (part-time founders are a structural red flag, not a stage-of-life accommodation), and demonstrated ability to recruit talent above their pay grade. Co-founder conflict already visible in due diligence does not improve under pressure; it compounds. The single most informative meeting is the one where the founders disagree in front of you and you watch how they resolve it.
Market: the ceiling sits here, not in the deck. A great team in a small or dying market produces a small or dying outcome. The TAM math in the previous subsection (section “Underwrite the Numbers, Not the Pitch”) is the floor of the underwriting; the qualitative questions sit on top of it. Is the market expanding, stable, or contracting? Is the founder fighting incumbents who already serve the customer adequately, or filling a void the customer is actively trying to fix? Is the timing right — the underlying enabling technology, regulation, or behavior shift already in place — or is the founder ten years early? Most failed startups had a competent team in a market that either did not yet exist or had already been won.
Co-investors: the cap table is a signal you can read for free. Who is already on the cap table tells you something without any modeling. A round led by a credible fund means another sophisticated party has already underwritten the deal at terms similar to yours, and that the company will have access to follow-on capital from a known source — the single highest-mortality risk for an early-stage company. A round filled exclusively with friends, family, and operators with no venture experience is a different proposition: you may still want the deal, but you are doing the underwriting work yourself rather than syndicating it with people who do this professionally for a living.
Valuation: cheap is not the same as good. The instinct to pay the lowest possible entry price is wrong at the venture stage. Entering at a high valuation in a company that will be worth ten times more is dominated only by not entering at all; entering at a low valuation in a company that will be worth zero is exactly as worthless as entering at a high one. The correct question is not “is this price low?” but “is this price low relative to what this company will plausibly be worth at the next round and at exit?” Sometimes the answer is yes at a $30M post-money and no at an $8M post-money on a different company. The valuation that matters is the exit valuation; the entry valuation matters only as a fraction of it.